Business Context and Reporting Period
This Form 8-K filing by Standard BioTools Inc. (Nasdaq: LAB) covers the reporting period of June 5, 2026. The filing addresses a specific regulatory event regarding the company's listing status on The Nasdaq Global Select Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a listing compliance event rather than financial performance.
Material Changes
The primary material change reported is the resolution of a listing deficiency. On April 20, 2026, the company received notice that its common stock closing bid price had fallen below $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5450(a)(1). As of June 5, 2026, the company received confirmation from Nasdaq that it has regained compliance with this Bid Price Requirement.
Outlook, Risks, and Management Commentary
Management commentary is limited to the confirmation that the matter regarding the minimum bid price requirement is now closed. The filing does not contain forward-looking guidance, new risk factors, contingencies, or unusual items beyond the previously disclosed listing deficiency.
Investor Verification Checklist
- Verify the current trading price of Standard BioTools Inc. (LAB) to ensure it remains above the $1.00 threshold.
- Confirm the duration of the compliance period required by Nasdaq to maintain the regained status.
- Review prior filings from April 2026 for details on the initial non-compliance notice.